Sage Journals: Discover world-class research

Abstract

Mannose-binding lectin (MBL) is a circulating protein that acts as a soluble pattern recognition molecule of the innate immunity. It binds to carbohydrate patterns on the surface of pathogens or of altered self-cells, with activation of the lectin pathway of the complement system. Recent evidence indicates that MBL contributes to the pathophysiology of ischemia-reperfusion injury and other conditions. Thus, MBL inhibitors offer promising therapeutic strategies, since they prevent the interaction of MBL with its target sugar arrays. We developed and characterized a novel assay based on surface plasmon resonance for in vitro screening of these compounds, which may be useful before the more expensive and time-consuming in vivo studies. The assay measures the inhibitor’s ability to interfere with the binding of murine MBL-A or MBL-C, or of human recombinant MBL, to mannose residues immobilized on the sensor chip surface. We have applied the assay to measure the IC₅₀ of synthetic glycodendrimers, two of them with neuroprotective properties in animal models of MBL-mediated injuries.

Keywords

surface plasmon resonance immunoassay mannose binding lectin inhibitor screening glycodendrimers

Introduction

Mannose-binding lectin (MBL) is a calcium-dependent (C-type) lectin, belonging to the collectin family, with an important role in innate immunity.¹ MBL circulates in blood complexed with MBL-serine proteases (MASPs) and acts as a soluble pattern recognition receptor, binding specific carbohydrate patterns exposed on the surface of pathogens or of “altered-self” cells through its carbohydrate-recognition domain (CRD). On binding the target cells, MASPs are activated, initiating the lectin pathway (LP) of the complement system.

MBL has been implicated in experimental models of myocardial,² renal,³ and gastrointestinal injury⁴; cerebral ischemia/reperfusion injury^5,6; and traumatic brain injury,^7,8 as well as preeclampsia.⁹ In all these conditions, MBL appears to contribute to tissue injury, and its deletion or inhibition is protective. MBL inhibitors might therefore be promising therapeutic strategies, and reliable in vitro assays are needed to identify them before more expensive and time-consuming in vivo studies.

MBL-binding properties of compounds can be investigated by a direct surface plasmon resonance (SPR) assay in which unlabeled putative MBL ligands are flowed onto recombinant MBL immobilized on the sensor chip.⁵ Binding is revealed in real time as a change of mass at the surface, and the interaction can be characterized in terms of on and off rates (kinetics) and binding strength.¹⁰ Although this approach is fairly straightforward and useful for initial screening purposes, it suffers some limitations: MBL can be bound on a site different from CRD, so it may not result in inhibitory activity; binding affinities can be overestimated due to multivalent interactions; immobilization procedures can alter the binding properties of MBL. We experienced difficulties in immobilizing recombinant murine MBL-C (mMBL-C, one of the two murine isoforms, together with mMBL-A¹¹). Then, last but not least, immobilization of MBL on a surface makes this configuration different from the physiological condition.

We have now developed and characterized a novel SPR-based assay that allows in vitro identification of MBL inhibitors, with a design that closely mimics real conditions, since the compound’s effects are measured by their ability to inhibit MBL binding to mannose residues exposed on the (sensor) surface. Thus, this approach can assess the inhibition of a property of MBL that is relevant to its functional activity. The assay is suited to study the inhibition of native plasmatic mMBL-A and mMBLC and of recombinant human MBL (rhMBL). We used it to measure the inhibitory effects of synthetic polymannosylated glycodendrimers, two of them—Polyman2 and Polyman9—with protective properties in animal models of MBL-mediated injuries.^5,8,9

Materials and Methods

Animals

Plasma was obtained from two 8-week-old C57Bl/6 mice (wild-type [WT], 20–25 g; Harlan Laboratories, Indianapolis, IN) and from a C57Bl/6 mouse with a target mutation of both MBL-A and MBL-C genes (MBL^−/−, 20–25 g, purchased from Jackson Laboratories [Bar Harbor, ME] and colonized at the Mario Negri Institute). Briefly, blood samples were collected from the vena cava in 10 mM ethylenediaminetetraacetic acid and 0.125% polybrene (Sigma-Aldrich, St. Louis, MO). Plasma was separated by centrifugation at 2000 g at 4 °C for 15 min, immediately stored, and kept at −80 °C until use.

The IRCCS–Istituto di Ricerche Farmacologiche Mario Negri adheres to the principles set out in the following laws, regulations, and policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorisation no. 19/2008-A, issued March 6, 2008, by the Ministry of Health), Mario Negri Institutional Regulations and Policies providing internal authorization for those conducting animal experiments (Quality Management System Certificate–UNI EN ISO 9001:2008–Reg. No. 6121), the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (2011 edition), and European Union (EU) directives and guidelines (EEC Council Directive 2010/63/UE). The Statement of Compliance (Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed (September 9, 2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01). The studies reported here were within a project specifically authorized by the Italian Ministry of Health (Decree no. 161/2014B).

SPR-Based Assay

SPR is a powerful label-free method widely used to study binding between two macromolecules.¹² Typically, one of the interacting partners is immobilized on a sensor chip surface, and the other is flowed through a microfluidic system in contact with the chip surface. Binding is revealed in real time as a change of mass at the surface. Although the most common application of SPR instruments is to determine affinity parameters for biomolecular interactions,¹⁰ its versatility permits many other uses, including label-free immunoassays.^13–15

The novel assay described here involves several steps. Figure 1 summarizes the four steps required for studies with murine plasma (two mMBL isoforms); studies with rhMBL are limited to the first two steps. The first step is the covalent immobilization of mannosylated bovine serum albumin (Man-BSA; Dextra Laboratories, Reading, UK) on the sensor chip (GLC; Bio-Rad, Hercules, CA) using amine coupling chemistry.¹⁶ Thus, Man-BSA molecules are bound to the sensor surface through the protein moieties, leaving the mannose residues exposed. The ProteOn XPR36 Protein Interaction Array system (Bio-Rad) used for these SPR studies has six parallel flow channels that can immobilize up to six ligands on the same sensor chip. In parallel to Man-BSA, we always immobilized BSA (Sigma) as reference. Immobilization levels were about 3000 and 4000 resonance units (RUs, 1 RU 1 pg protein/mm²). After the first immobilization step, the ProteOn XPR36 fluidic system was rotated 90°¹⁷ so that up to six different solutions could be injected simultaneously over the immobilized ligands ( Fig. 1 ). In this second step, we injected MBL-containing solutions, preincubated with or without the inhibitors (see below). We used mouse and human plasma, diluted (as indicated) in 10 mM running buffer (Tris buffer containing 150 mM NaCl and 0.005% Tween-20 [pH 7.4], plus 1.2 mM CaCl₂) or running buffer with rhMBL added (R&D Systems, Minneapolis, MN). This second step aims to capture MBL (mMBL isoforms or rhMBL) on the Man-BSA surface. The mannose-dependent SPR binding signal is obtained by subtracting the mannose-independent nonspecific response on the reference surface (BSA only). The following steps are carried out after further rotation of the fluidic system ( Fig. 1 ) and regards the sequential injections of anti-MBL antibodies. After injecting murine plasma, we injected 10 µg/mL anti–mMBL-A and 10 µg/mL anti–mMBL-C antibodies (Hycult Biotech, Uden, the Netherlands) to specifically recognize and quantify the isoform captured during the second step ( Fig. 1 ). Two anti-hMBL antibodies were tested after injection of human plasma: 10 µg/mL anti-hMBL antibody 3E7 (Hycult Biotech) and 10 µg/mL anti-hMBL antibody 3B6 (Abcam, Cambridge, UK). All SPR assays were run at 25 °C. The sensorgrams (time course of the SPR signal in RU) were normalized to a baseline of 0.

Figure 1.

Schematic summary of the surface plasmon resonance assay for inhibitors of murine mannose-binding lectin (MBL) isoforms. Man-BSA, mannosylated bovine serum albumin.

For the analysis of putative MBL inhibitors, diluted plasma or running buffer spiked with rhMBL was preincubated for 30 min at 25 °C, with or without glycodendrimers at different concentrations, and then flowed onto immobilized Man-BSA and BSA ( Fig. 1 , step 2). The six parallel flow channels meant we could analyze the effect of up to four concentrations simultaneously, leaving one for mouse plasma preincubated with vehicle alone (total binding, TB) and one channel for MBL^−/− mouse plasma (nonspecific binding, NSB). Since samples are flowed for 10 min at a rate of 30 µL/min, a volume of 400 µL is required for each of them; thus, 2 mL of diluted plasma is needed for the 5-point inhibition curve described above. This means that the plasma from a single mouse (about 200 µL), diluted 100-fold, allows to analyze 10 inhibition curves (e.g., three compounds in triplicate), considering both mMBL-A and mMBL-C.

The SPR binding signal at t = 100 s, in the presence of each drug concentration (binding with drug, BD), was used to calculate the percentage inhibition of specific binding (%INH-SB) as follows:

% INH - SB = ((TB - BD) / (TB - NSB)) * 100 .

The aim of these studies was to identify compounds that prevent the MBL interaction with mannose residues and to determine their potency, that is, the concentration inhibiting MBL binding by 50% (IC₅₀).

Synthetic Polymannosylated Glycodendrimers

The glycodendrimers we tested as MBL inhibitors are shown in Figure 2 . They are Polyman2 (also referred to as Dendron 12,¹⁸ which is a tetravalent glycodendron carrying a pseudo-trimannoside headgroup); Polyman9, a hexavalent glycodendrimer with a flexible core, carrying a pseudo-dimannoside headgroup (also referred to as glycodendrimer 13.3¹⁹); and Polyman31, a hexavalent glycodendron carrying the same pseudo-dimannoside headgroup on a rigid-core architecture.²⁰ The synthesis and characterization of these compounds have been described previously.^18–20

Figure 2.

Structures of the glycodendrons used in this study: Polyman2, Polyman9, and Polyman31.

Results

Characterization of the SPR Assay for mMBL-A and mMBL-C

Diluted plasma from WT mice injected over a sensor surface coated with Man-BSA resulted in a marked SPR signal (2550 and 1500 RU, on average, at plasma dilutions of 1:50 and 1:100, respectively), much higher than in a parallel reference surface coated with BSA only (800 RU and 530 RU) (representative sensorgrams in Suppl. Fig. S1A). This indicated the presence of a mannose-dependent binding signal, highlighted in sensorgrams obtained by subtracting the signal in the reference surface (Suppl. Fig. S1B and Fig. 3A). Most of this specific signal was due to mMBL, since plasma from the MBL^−/− mice gave a much lower specific signal, only 20% ± 11% of the WT plasma value (mean ± SD, n = 18) ( Fig. 3A and Suppl. Fig. S1B).

Figure 3.

Capture of plasmatic mMBL-A and mMBL-C by immobilized mannose residues. (A) Representative sensorgrams (i.e., time course of surface plasmon resonance [SPR] signal in resonance units, RU) with plasma (1:50) from wild-type (WT) and MBL^−/− (knockout [KO]) mice injected over chip surfaces coated with mannosylated bovine serum albumin (Man-BSA). These sensorgrams were obtained after subtraction of the nonspecific signal measured on a parallel surface coated with BSA (see also Suppl. Fig. S1). Plasma was injected for 10 min (bars). (B, C) Representative sensorgrams with sequential injections of anti–MBL-A or anti–MBL-C antibodies shortly after the injection of plasma.

The binding of plasmatic mMBL to immobilized mannose residues was very stable, as shown by the low dissociation rates after the injections ( Fig. 3A ), thus allowing sequential injection of the antibodies against mMBL-A and mMBL-C. These injections resulted in clear SPR binding signals ( Fig. 3B , C ), indicating that both murine isoforms were actually captured during the plasma injection; much lower signals were observed in the surfaces where plasma from MBL^−/− had been flowed (23% ± 16% and 11% ± 13% with antibodies against mMBL-A and mMBL-C, mean ± SD, n = 18), thus confirming the specificity of the measured signal. The SPR signal with the anti–mMBL-A antibody was linear during the injection period, whereas a plateau was reached during the injection of the anti–mMBL-C antibody. This indicates a higher association rate constant of the anti–mMBL-C than the anti–mMBL-A antibody and that less mMBL-C than mMBL-A was captured by mannose.

As expected, the binding signals due to both mMBL-A and mMBL-C correlated with plasma dilution (Suppl. Fig. S2A,B), although there was a tendency to saturation with the highest concentrations (1:50 and 1:25). The IC₅₀ was determined using plasma diluted at either 1:50 or 1:100, with no significant differences in the results.

Preincubation of plasma with different concentrations of mannose resulted in concentration-dependent inhibition of both mMBL-A and mMBL-C binding to immobilized mannose, as indicated by the subsequent injections of the corresponding antibodies. The IC₅₀ was similar for the two isoforms, respectively 5.4 and 5.2 mM for mMBL-A and mMBL-C.

Characterization of the Assay for hMBL

Injection of diluted human plasma over immobilized Man-BSA resulted in a marked SPR signal (400 RU on average, at plasma dilutions of 1:50), much higher than that observed in a parallel reference surface coated with BSA only (50 RU) (representative sensorgrams in Suppl. Fig. S1C). This indicated the presence of a mannose-dependent binding signal (i.e., obtained by subtraction of the signal in the reference surface), although this was much lower than with murine plasma (Suppl. Fig. S1D vs. Suppl. Fig. S1B).

Despite the presence of a mannose-dependent binding signal, we were not able to confirm the capture of hMBL with anti-hMBL antibodies. Results were negative with two different anti-hMBL antibodies, at concentrations up to 10 µg/mL, even when plasma was only diluted 1:10 (data not shown). To overcome this problem, we developed a different approach testing the compounds for their ability to inhibit the binding of rhMBL to immobilized mannose. A very similar approach, using BSA-conjugated N-acetyl-D-glucosamine as immobilized sugar, has already been applied.²¹ Different concentrations of rhMBL (Suppl. Fig. S2C), diluted in running buffer, resulted in a concentration-dependent binding signal, linear in the 0.5 to 8 nM range (Suppl. Fig. S2D). Global fitting of these sensorgrams according to the simplest 1:1 interaction model (Langmuir model) gave an estimated K_D of 1 nM.

Inhibitory Effects of Polymannosylated Glycodendrimers

Polyman2 inhibited the binding of mMBL-A and mMBL-C to immobilized mannose with similar IC₅₀ values (93 and 84 µM; Fig. 4A , B ), whereas Polyman31 was highly selective for the two isoforms, inhibiting mMBL-C with a very low IC₅₀ (0.5 µM) but being much less active on mMBL-A (IC₅₀ >200 µM) ( Fig. 4A , B ). Polyman9 also had a lower IC₅₀ on mMBL-C (65 µM) than on mMBL-A (IC₅₀ >200 µM) ( Fig. 4A , B ).⁸

Figure 4.

Inhibitory effect of dendrimeric compounds on mMBL-A (A), mMBL-C (B), or rhMBL (C) binding to mannose residues. Polyman31 is indicated in blue, Polyman2 in red, and Polyman9 in green (data of Polyman9 from De Blasio et al.⁸). Each value is the mean ± SD of two to three independent surface plasmon resonance (SPR) sessions.

As an example of raw data, Supplemental Figure S3A shows representative sensorgrams obtained by injecting plasma preincubated or not with 3 µM Polyman31, in parallel with plasma from MBL^−/− mice. At this concentration, Polyman31 had no effect on MBL-A binding (Suppl. Fig. S3B), but it reduced MBL-C binding by 85% (Suppl. Fig. S3C). The 20% decrease during the plasma injection (Suppl. Fig. S3A) indicated that most (~ 77%) of the MBL captured by mannose was accounted for by MBL-A.

Preincubation of rhMBL (8 nM) with different concentrations of dendrimers resulted in dose-dependent inhibition of rhMBL binding to immobilized mannose ( Fig. 4C ). In this assay, Polyman31 was the most potent inhibitor (IC₅₀ = 62 µM), followed by Polyman9 (~136 µM) and Polyman2 (~270 µM).

Discussion

We report the characterization of a novel SPR assay for in vitro screening of MBL inhibitors, analyzed for their ability to interfere with MBL binding to carbohydrate patterns. This was achieved by flowing MBL-containing solutions, with or without inhibitors, over a sensor chip exposing mannose residues.

The mannose-dependent SPR signal with diluted murine plasma is mostly (80% on average) due to mMBL, as indicated by the results with plasma of MBL^−/− mice. This binding has a very low dissociation rate, as expected for multivalent binding, thereby permitting subsequent injections of antibodies against mMBL-A and mMBL-C to specifically recognize and quantify the isoform captured by mannose. In our conditions, 70% to 80% of the mMBL-dependent SPR signal is accounted for by mMBL-A, although its serum levels in C57Bl/6 mice are four to five times lower than those of mMBL-C.^22,23 Since the molecular mass of the two isoforms is comparable,²² this suggests that mMBL-A has greater affinity than mMBL-C for immobilized mannose. To our knowledge, there are no data available in literature comparing the binding of native plasmatic murine MBL isoforms to surface mannose arrays (i.e., using a design mimicking the physiological condition). Consistently with our observation, it was previously reported that the CRD domain of the A isoform of the rat mannose binding protein (MBP-A) had 14-fold higher affinity for mannosylated BSA than the CRD domain of MBP-C.²⁴ Regarding murine MBL isoforms, the only available data showed that monovalent mannose inhibited the binding of purified mMBL-A and mMBL-C to mannan-coated wells with an IC₅₀ of 1.5 and 4 mM, respectively.¹¹ Measuring the effect of mannose on the binding of plasmatic mMBL-A and mMBL-C to mannose-coated chips, we could not confirm this slight difference between the two isoforms (IC₅₀ = 5.4 and 5.2 mM, respectively). The physiological relevance of monovalent sugar affinity, however, is limited, since it is well known that the binding of MBL to mannose patterns exposed on a cell surface involves multivalent protein-sugar interactions that significantly increase the overall binding affinity. It might be speculated that the different affinities of plasmatic mMBL-A and mMBL-C for immobilized mannose arrays could be due to a different CRD conformation, with consequences on the avidity effects. The smaller proportion of mMBL-C captured by immobilized mannose was, however, compensated by the higher affinity of the corresponding antibody. Thus, the SPR signal 100 s after injection of the anti–mMBL-C antibody was similar, on average, to that seen 100 s after injection of the anti–mMBL-A antibody.

The SPR data obtained injecting diluted human plasma indicated a mannose-dependent binding signal that, however, could not be definitely associated with the capture of hMBL. In fact, there was no SPR signal on subsequent injection of anti-hMBL antibodies. Possibly, the “mannose-dependent” binding signal after injection of human plasma is either (1) not due to hMBL capture or (2) actually due to hMBL, but the two anti-hMBL antibodies tested did not bind it efficiently enough for detection in our setup.

The mannose-dependent binding signal with human plasma was much lower (20%) than the signal with murine plasma, in agreement with the lower hMBL concentration (1–1.5 µg/mL)^25,26 than mMBL-A (8–20 µg/mL) or mMBL-C (30–100 µg/mL).^22,23 Insufficient capture of hMBL on the sensor chip might thus contribute to the lack of measurable binding with anti-hMBL antibodies, although results were also negative using plasma or serum diluted 10-fold only. Other factors required for an efficient SPR assay, and possibly not met with native hMBL, are (1) adequate affinity of hMBL for the immobilized mannose residues, particularly an association rate constant permitting the capture of enough hMBL during the short association phase (few minutes), and/or (2) suitable affinity of the anti-hMBL antibodies employed for these studies. In this regard, successful detection of plasmatic mMBL-A is very likely due to its high affinity for immobilized mannose (higher than that of mMBL-C), whereas successful detection of mMBL-C is probably likely due to the high serum concentrations and the high affinity of the anti–mMBL-C antibody (higher than that of anti–mMBL-A antibody).

To evaluate the effects of potential inhibitors on hMBL, we developed an SPR assay using rhMBL. A suitable SPR binding signal was obtained by flowing 8 nM rhMBL, dissolved in buffer (about 2.7 µg/mL; i.e., much higher than the concentration present in diluted human plasma), while lower concentrations gave proportionally lower SPR signals.

We used these assays to study the inhibitory effects of synthetic polymannosylated glycodendrimers. Native MBL is found as oligomers of a trimeric building block, with multiple CRD domains²⁷ that efficiently bind to carbohydrate patterns through multivalent protein-sugar interactions. Thus, to interfere with these, multivalent inhibitors such as glycodendrimers have been designed and studied over the past 10 years as potential antagonists.^28,29 Polyman2¹⁸ is a tetravalent pseudo-trimannoside dendron that showed potent protective activity in mouse models of cerebral ischemia⁵ or preeclampsia,⁹ where MBL significantly contributed to the injury. Polyman9 is a hexavalent pseudo-dimannoside dendrimer based on a flexible scaffold¹⁹ that showed neuroprotective effects in a murine model of traumatic brain injury.⁸ Polyman31 is a new hexavalent pseudo-dimannoside dendrimer based on a rigid-core architecture.²⁰ In our assay, Polyman2 showed no selectivity between mMBL-A and mMBL-C (IC₅₀ = 93 and 84 µM), whereas Polyman31 had a completely different interaction profile, being very potent on MBL-C (IC₅₀ = 0.5 µM) but almost inactive on mMBL-A up to 200 µM. Polyman9 had a similar profile, inhibiting mMBL-C (IC₅₀ = 65 µM) but not MBL-A (IC₅₀ >>200 µM).⁸ These molecules also inhibited rhMBL binding to mannose residues, with an IC₅₀ from 62 to 270 µM. The MBL-C selectivity observed with Polyman31 and Polyman9 is likely due to intrinsic structural features of these dendrimers, since the lack of selectivity of Polyman2 excludes methodological artifacts. The occupation of CRD mannose-binding sites by dendrimers depends on the affinity of the sugar residues and on their spatial arrangement. Polyman31 and Polyman9 carry pseudo-dimannoside headgroups, whereas a pseudo-trimannoside headgroup is present in Polyman2. It could also be envisaged that sterical hindrance could play a role even with a partial CRD occupation, depending on the dendrimer and CRD sizes. In our test, the proteins are present in their native plasmatic form, which is likely to consist of aggregates of CRD trimers.^11,22 The distance between binding sites in trimers is estimated to be ~5 nm for hMBL.^30,31 The higher affinity of Polyman31 for mMBL-C may reflect a better match between this molecule, where two active ligands can span a distance of 4 to 5 nm, and the MBL-C trimer. The size and composition of the higher order oligomers are less understood,³² whereas our data exclude the aggregation of the dendrimers (not shown).

The inhibitor concentrations we used (µM range) greatly exceed those of MBL (nM range, in diluted murine plasma and rhMBL). Thus, the percentage inhibition of MBL binding to mannose is indicative of the occupancy of MBL proteins, and the IC₅₀ is a measure of the inhibitor’s affinity for MBL. The affinities of Polyman2 for mMBL-A and rhMBL (IC₅₀ = 93 and ~270 µM) are higher than those measured by direct SPR assay—that is, directly flowing the dendrimer over immobilized recombinant mMBL-A (K_D = 4.7 µM, data not shown) or rhMBL (K_D = 6 µM⁵). A similar difference was reported for polymeric inhibitors of the lectin DC-SIGN using analogous SPR approaches¹⁵ and is possibly due to a lower impact of avidity effects when interactions occur in solution. Moreover, since each MBL molecule has multiple CRD domains, it may be envisaged that occupation of most of them is necessary for inhibition of its binding to immobilized mannose, whereas binding to a single CRD is enough to elicit an SPR signal in the direct SPR assay. We consider the IC₅₀ values obtained with the proposed indirect SPR assay more informative since they measure the ability of the compounds to interfere with the main final physiological event to be targeted by MBL inhibitors (i.e., the binding of native mMBL to mannose arrays).

A mannan immunoassay has been described in which murine plasma was incubated on mannan-coated microtiter wells and murine MBL isoforms were then recognized by biotinylated anti-MBL antibodies and europium-labeled streptavidin.²² This method was used to quantify mMBL-A and mMBL-C concentrations in mouse sera, but to our knowledge, it has never been used to screen MBL inhibitors. In comparison with our SPR assay, immunoassays in microtiter wells are probably more sensitive, due to signal amplification. However, the SPR assay has other worthwhile advantages: (1) it does not need any labeled reagent and takes less of the antibodies than for microtiter wells; (2) the amount of bound anti-MBL antibody—and thus MBL—is immediately determined by SPR, whereas further steps are required when using microtiter wells (e.g., incubation with europium-labeled streptavidin for an immunofluorometric assay)²²; and (3) the long incubation of plasma in mannan-coated microtiter wells may reduce the binding between the inhibitor and plasmatic MBL, due to the equilibrium shift induced by the high-affinity binding of free MBL to immobilized sugars; this potential artifact, leading to underestimation of the compound’s inhibitory effect, is probably absent during the very short flow of plasma over the mannose-coated SPR surface.

In conclusion, we have extensively characterized a novel assay, convenient for in vitro screening of putative MBL inhibitors, to select the appropriate compounds for the more expensive and time-consuming in vivo studies. This approach has been successfully used to identify a selective mMBL-C inhibitor, Polyman9, which conferred neurobehavioral protection when given shortly after traumatic brain injury.⁸ We also found another glycodendrimer, Polyman31, with even higher affinity and selectivity for mMBL-C.

Footnotes

Supplementary material for this article is available on the Journal of Biomolecular Screening Web site at .

Declaration of Conflicting Interests

The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support, including a fellowship to D. De Blasio, was provided by Fondazione Cariplo (grant number 2012-0590).

References

Endo

Matsushita

Fujita

New Insights into the Role of Ficolins in the Lectin Pathway of Innate Immunity. Int. Rev. Cell. Mol. Biol. 2015, 316, 49–110.

Walsh

M. C.

Bourcier

Takahashi

. Mannose-Binding Lectin Is a Regulator of Inflammation That Accompanies Myocardial Ischemia and Reperfusion Injury. J. Immunol. 2005, 175, 541–546.

de Vries

Walter

S. J.

Peutz-Kootstra

C. J.

. The Mannose-Binding Lectin-Pathway Is Involved in Complement Activation in the Course of Renal Ischemia-Reperfusion Injury. Am. J. Pathol. 2004, 165, 1677–1688.

Hart

M. L.

Ceonzo

K. A.

Shaffer

L. A.

. Gastrointestinal Ischemia-Reperfusion Injury Is Lectin Complement Pathway Dependent without Involving C1q. J. Immunol. 2005, 174, 6373–6380.

Orsini

Villa

Parrella

. Targeting Mannose-Binding Lectin Confers Long-Lasting Protection with a Surprisingly Wide Therapeutic Window in Cerebral Ischemia. Circulation 2012, 126, 1484–1494.

Gesuete

Storini

Fantin

. Recombinant C1 Inhibitor in Brain Ischemic Injury. Ann. Neurol. 2009, 66, 332–342.

Longhi

Orsini

De Blasio

. Mannose-Binding Lectin Is Expressed after Clinical and Experimental Traumatic Brain Injury and Its Deletion Is Protective. Crit. Care Med. 2014, 42, 1910–1918.

De Blasio

Fumagalli

Longhi

. Pharmacological Inhibition of Mannose Binding Lectin Ameliorates Neuro-behavioral Dysfunction following Experimental Traumatic Brain Injury. J. Cereb. Blood Flow Metab. 2015, submitted for publication.

Petitbarat

Durigutto

Macor

. Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. J. Immunol. 2015, 195, 5602–5607.

10.

Cooper

M. A.

Optical Biosensors in Drug Discovery. Nat. Rev. Drug Discov. 2002, 1, 515–528.

11.

Hansen

Thiel

Willis

. Purification and Characterization of Two Mannan-Binding Lectins from Mouse Serum. J. Immunol. 2000, 164, 2610–2618.

12.

Rich

R. L.

Myszka

D. G.

Higher-Throughput, Label-Free, Real-Time Molecular Interaction Analysis. Anal. Biochem. 2007, 361, 1–6.

13.

Mullett

W. M.

Lai

E. P.

Yeung

J. M.

Surface Plasmon Resonance-Based Immunoassays. Methods 2000, 22, 77–91.

14.

Canovi

Lucchetti

Stravalaci

. A New Surface Plasmon Resonance-Based Immunoassay for Rapid, Reproducible and Sensitive Quantification of Pentraxin-3 in Human Plasma. Sensors (Basel) 2014, 14, 10864–10875.

15.

Zhang

Collins

Anastasaki

. Sequence-Controlled Multi-Block Glycopolymers to Inhibit DC-SIGN-gp120 Binding. Angew Chem. Int. Ed. Engl. 2013, 52, 4435–4439.

16.

Gjelstrup

L. C.

Kaspersen

J. D.

Behrens

M. A.

. The Role of Nanometer-Scaled Ligand Patterns in Polyvalent Binding by Large Mannan-Binding Lectin Oligomers. J. Immunol. 2012, 188, 1292–1306.

17.

Bravman

Bronner

Lavie

. Exploring “One-Shot” Kinetics and Small Molecule Analysis Using the ProteOn XPR36 Array Biosensor. Anal. Biochem. 2006, 358, 281–288.

18.

Sattin

Daghetti

Thepaut

. Inhibition of DC-SIGN-Mediated HIV Infection by a Linear Trimannoside Mimic in a Tetravalent Presentation. ACS Chem. Biol. 2010, 5, 301–312.

19.

Varga

Sutkeviciute

Ribeiro-Viana

. A Multivalent Inhibitor of the DC-SIGN Dependent Uptake of HIV-1 and Dengue Virus. Biomaterials 2014, 35, 4175–4184.

20.

Ordanini

Varga

Porkolab

. Designing Nanomolar Antagonists of DC-SIGN-Mediated HIV Infection: Ligand Presentation Using Molecular Rods. Chem. Commun. (Camb.) 2015, 51, 3816–3819.

21.

Montalto

M. C.

Collard

C. D.

Buras

J. A.

. A Keratin Peptide Inhibits Mannose-Binding Lectin. J. Immunol. 2001, 166, 4148–4153.

22.

Liu

Jensen

Hansen

. Characterization and Quantification of Mouse Mannan-Binding Lectins (MBL-A and MBL-C) and Study of Acute Phase Responses. Scand. J. Immunol. 2001, 53, 489–497.

23.

Shushimita

van der Pol

de Bruin

R. W. F.

. Mannan-Binding Lectin Is Involved in the Protection against Renal Ischemia/Reperfusion Injury by Dietary Restriction. PLoS One 2015, 10, e0137795.

24.

Childs

R. A.

Feizi

Yuen

C. T.

. Differential Recognition of Core and Terminal Portions of Oligosaccharide Ligands by Carbohydrate-Recognition Domains of Two Mannose-Binding Proteins. J. Biol. Chem. 1990, 265, 20770–20777.

25.

Zanier

E. R.

Zangari

Munthe-Fog

. Ficolin-3-Mediated Lectin Complement Pathway Activation in Patients with Subarachnoid Hemorrhage. Neurology 2014, 82, 126–134.

26.

Osthoff

Katan

Fluri

. Mannose-Binding Lectin Deficiency Is Associated with Smaller Infarction Size and Favorable Outcome in Ischemic Stroke Patients. PLoS One 2011, 6, e21338.

27.

Drickamer

Dordal

M. S.

Reynolds

Mannose-Binding Proteins Isolated from Rat Liver Contain Carbohydrate-Recognition Domains Linked to Collagenous Tails: Complete Primary Structures and Homology with Pulmonary Surfactant Apoprotein. J. Biol. Chem. 1986, 261, 6878–6887.

28.

Bernardi

Jimenez-Barbero

Casnati

. Multivalent Glycoconjugates as Anti-Pathogenic Agents. Chem. Soc. Rev. 2013, 42, 4709–4727.

29.

Imberty

Chabre

Y. M.

Roy

Glycomimetics and Glycodendrimers as High Affinity Microbial Anti-Adhesins. Chemistry 2008, 14, 7490–7499.

30.

Sheriff

Chang

C. Y.

Ezekowitz

R. A.

Human Mannose-Binding Protein Carbohydrate Recognition Domain Trimerizes through a Triple Alpha-Helical Coiled-Coil. Nat. Struct. Biol. 1994, 1, 789–794.

31.

Weis

W. I.

Drickamer

Trimeric Structure of a C-Type Mannose-Binding Protein. Structure 1994, 2, 1227–1240.

32.

Miller

Phillips

Gor

. Near-Planar Solution Structures of Mannose-Binding Lectin Oligomers Provide Insight on Activation of Lectin Pathway of Complement. J. Biol. Chem. 2012, 287, 3930–3945.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.23 MB

0.00 MB